Adel Aali
Irvine, CA (USA)
Role(s):
Active Funding Request
This user has an Active Funding Request. You must be logged in as an approved, accredited investor to view this Funding Request. Call us at 888-391-7096 to apply.
C-Level Executive (CEO, CFO, etc.)
Aalnex, Inc.
Find More Startups
Startup
Location:
Irvine
Industry:
Healthcare
Year Founded:
2011
Number Employees:
1-10 people
Business Stage:
Growth (not profitable)
Entity Type:
"C" Corporation
Description:
Aalnex, Inc., is a medical device company that has developed an entirely novel and game-changing wound care technology for treatment of hard-to-heal chronic wounds that annually afflict well more than six million, mostly elderly Americans. Examples of such wounds include diabetic foot ulcers, pressure ulcers (bedsores), and venous leg ulcers. Wound patients generate costs of care in excess of $62.5 billion – a figure growing at 6% annually.
Preliminary clinical results have demonstrated that Aalnex’s Sepaderm® technology has the following advantages over its competitors: (1) heals wounds at a faster rate, (2) causes no pain, whereas competitors’ products cause various levels of pain, and (3) is less expensive. Two Sepaderm product lines commercially succeeded in a test market, and seven other product lines are in various stages of design and development. Aalnex’s technology is protected by a formidable patent portfolio in North America, Europe, Asia and Australia. With potential for high profit margins, the Sepaderm products are poised to penetrate a very large market that is growing at double digits on annual basis. Aalnex’s accomplishments have been made in the course of three years with less than $2 million in total investment.
Since most Sepaderm product lines have FDA marketing clearance, the next step for Aalnex is market development, which includes medical marketing along with simultaneous sales in defined geographic regions. Aalnex is currently raising funds for its market development stage.